– Kenneth Anderson, medical director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber and author of the paper, the results of can we predict how patients on current treatments based on a genetic analysis of their response disease. In addition, the results identify many new genes in the cause and progression of myeloma involved, and the product of these genes can be targeted with new therapies. .. Not only the findings pave the way for treatments tailored to a patient’s specific form of the disease, but also narrow down areas of the chromosomes in myeloma cells likely to contain undiscovered genetic defects that drive myeloma, and which might be vulnerable to targeted designer drugs.
###by grants from the by grants from the National Cancer Institute, the Myeloma Cure Fund and the Belfer Foundation for Innovative computer science at Dana-Farber.Dana-Farber Cancer Institute (a principal teaching affiliate of Harvard Medical School and is among the leading cancer research and care in the U.S. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF. A designated Comprehensive Cancer Center of the National Cancer Institute.Was awarded the Dr. Model of cerebral malarial – Burroughs Wellcome Fund Choosing of Einstein Dr. Mahalia Desruisseaux for the 2007 Career Award in medical Scientists.